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Objective: To compare the efficacy and safety of twice daily valaciclovir with five times daily
aciclovir in the treatment of an episode of recurrent genital herpes simplex virus (HSV) infection
in immunocompetent individuals.
Methods: 739 patients with a history of recurrent genital HSV infection received either oral
valaciclovir (500 mg twice daily) or aciclovir (200 mg five times daily) for 5 days for treatment of
their next recurrent episode in a controlled, randomised, double blind trial. Patients self initiated
therapy at the first signs and/or symptoms of the HSV recurrence, then were assessed in clinic on
five occasions over 7 days, and twice weekly thereafter until lesions had healed. Safety was eval-
uated through adverse experience reports and haematology and biochemistry monitoring.
Results: No significant differences were detected between valaciclovir and aciclovir for the pri-
mary endpoint, the duration of all signs and symptoms which included lesion healing and
pain/discomfort. The hazard ratio [95% confidence interval] for valaciclovir v aciclovir was 0 93
[0.79, 1.08]. Lesion healing time was similar in each treatment group (hazard ratio valaciclovir v
aciclovir 0.96 [0.80, 1.14]). The odds ratio of valaciclovir v aciclovir in preventing the develop-
ment of vesicular/ulcerative lesions was 1-08 [0.82, 1.42]. Percentages of patients in whom all
HSV cultures were negative were similar in the valaciclovir and aciclovir groups at 59% and 54%
respectively; for patients having equal to or more than one positive culture result after treatment
initiation, cessation of virus shedding was similarly rapid for the two treatments (hazard ratio
0-98 [0.75, 1 .27]). The safety profiles of valaciclovir and aciclovir were comparable with adverse
experiences being infrequent and generally mild.
Conclusion: This study has demonstrated that valaciclovir 500 mg twice daily is equivalent in
efficacy to aciclovir 200 mg five times daily as episodic treatment of recurrent genital HSV infec-
tion. Valaciclovir maintains the established efficacy and safety of aciclovir but offers a much
more convenient twice daily dosing regimen.
(Genitourin Med 1997;73:110-116)
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Introduction
Genital herpes simplex virus (HSV) infection
continues to be a major public health problem
throughout the world. Epidemiological sur-
veys undertaken in both industrialised and
developing countries indicate that the preva-
lence of HSV infection is rising rapidly, and
HSV is now the most common cause of genital
ulceration in many countries.' The seropreva-
lence of HSV-2 is highest in Africa (30-40%)
followed by the USA (13-40%) and Europe
(7-16 %).2 Studies show an annual acquisition
rate of 2-4% for HSV-2 depending upon the
population studied.2 3 Over the past decade,
aciclovir (Zovirax) has become the therapy of
choice for the management of recurrent geni-
tal HSV infection.'46 The recommended oral
regimen of 200 mg five times daily for five
days has been shown to reduce lesion healing
time and shorten the course of virus shedding
when treatment is initiated within 24 hours of
the first signs and/or symptoms of a recurrent
HSV episode.78 Early treatment may prevent
the development of vesicular or ulcerative
lesions in some patients if treatment is initi-
ated during the prodrome.8
Over 15 years of clinical experience has
shown aciclovir to be an effective and well
tolerated drug for the management of HSV
infections.51' However, its limited oral
bioavailability (10-20%) and short plasma
elimination half life mean that frequent dosing
is required. A formulation providing higher
oral aciclovir bioavailability would therefore
improve upon its clinical usefulness.'2
Valaciclovir (Valtrex, Zelitrex) is the L-valyl
ester of aciclovir and once absorbed, is rapidly
and almost completely converted to aciclovir
and the essential amino acid, L-valine after
oral administration. The absolute bioavailabil-
ity of aciclovir after oral valaciclovir adminis-
tration is 54%, a three- to fivefold increase
over oral aciclovir itself.'3 14 Two controlled
studies comparing valaciclovir with placebo
and with aciclovir and placebo as episodic
treatment for recurrent genital HSV infection
have shown that both active therapies are
effective in speeding resolution of signs and
symptoms.'5 16 The present study was under-
taken to investigate whether the efficacy of
valaciclovir twice daily could be maintained
with the lower unit dose of 500 mg.
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Patients and methods
STUDY DESIGN
This was a multicentre, randomised, double
blind comparison of twice daily valaciclovir
and five times daily aciclovir given for five days
for the treatment of a single episode of recur-
rent genital herpes infection. For the purpose
of this study, genital herpes was defined as a
history of recurrent HSV infection involving
genital, perianal, or closely related sites.
PATIENTS
Male and female patients of at least 18 years of
age were eligible to enter the study if they had
experienced four or more recurrences of genital
HSV reactivation in the previous 12 months.
Those who had been previously receiving sup-
pressive aciclovir had to have experienced a
recurrence within three months of stopping
therapy and within the three months before
enrolment into the study in order to be eligi-
ble. Patients were not eligible if they had sig-
nificant hepatic or renal impairment, were
pregnant or nursing mothers, had malabsorp-
tion syndrome, were immunocompromised,
known to be HIV seropositive, or were receiv-
ing probenecid, other systemic antiviral med-
ications, or immunomodulatory treatment.
Ethics committee approval was obtained at
each study site before recruitment commenced
and all patients gave full written informed con-
sent.
STUDY PROCEDURES
Eligible patients were screened then ran-
domised in equal numbers to one of two treat-
ment arms-oral valaciclovir 500 mg twice
daily or oral aciclovir 200 mg five times daily
for five days. A blood sample was taken at the
screening visit for baseline haematology and
clinical chemistry, and to determine HSV-2
serological status if there was no record of a
positive HSV culture during the study or a
documented history of culture proved genital
HSV infection in the patient's usual medical
record. Serological testing was by western blot
at a single reference laboratory. Pregnancy
tests were performed on all females of child-
bearing potential at screening and again on the
first day of treatment (day 1).
Study medication was dispensed at screen-
ing. Patients randomised to valaciclovir also
received placebo (dummy) aciclovir tablets;
those randomised to aciclovir also received
placebo valaciclovir tablets.
Patients self initiated treatment at the first
signs or symptoms of their next recurrence.
Signs and symptoms included mucocutaneous
lesions and/or pain or discomfort. They
attended the clinic for evaluation within 24
hours of starting medication. Clinical evalua-
tion and staging of external lesions (macule/
papule, vesicle/ulcer, crust, or healed) was per-
formed on days 1, 2, 3, 5, and 7. Patients
attended the clinic twice weekly thereafter if
lesions had not healed by day 7. Diaries were
used throughout the treatment and follow up
period for patients to record the date and time
of prodrome/first signs of genital lesions, com-
pliance with the dosing schedule, the patient's
own assessment of lesion healing, and the
pain/discomfort level (no pain, mild, moder-
ate, or severe pain). Swabs for HSV culture
were taken at each clinic visit until all lesions
had healed. Virus isolation was performed at a
single reference laboratory in each city accord-
ing to local protocol. Safety was assessed by
adverse experience reporting at each visit and
from haematology (haemoglobin, white blood
cell, and platelet counts) and clinical chem-
istry (creatinine, alkaline phosphatase, and
AST or ALT) evaluations on days 1 and 5.
Blood was drawn for determination of steady
state plasma aciclovir concentrations by
radioimmunoassay on days 2 and 5.17
Compliance was assessed by pill count of
returned blister packs. All patients who did
not start treatment were asked to return
unused study medication.
EFFICACY ENDPOINTS
The primary efficacy endpoint on which the
sample size calculation was based was length
of episode, which was defined as the number
of days from treatment initiation to complete
resolution of all signs and symptoms. In the
majority of patients, genital HSV lesions were
expected to progress through the usual stages
of vesiculation or ulceration, and scabbing
before healing.'5 Lesion healing time was
therefore also considered a primary efficacy
endpoint and was defined as the number of
days between initiation of treatment and com-
plete re-epithelialisation of all mucocutaneous
lesions. Secondary endpoints were whether or
not the HSV episode aborted (defined by the
presence of symptoms such as pain/discomfort
but failure of lesions to develop beyond the
macule/papule stage), duration and severity of
pain/discomfort, percentages of patients hav-
ing no positive HSV culture after treatment
initiation, and duration of virus shedding in
those patients having at least one positive HSV
culture.
SAMPLE SIZE CALCULATION
The minimum sample size of 250 treated
patients per arm provided sufficient power to
detect differences between treatments in the
duration of all signs and symptoms, assuming
proportional hazards functions. The sample
size provided 80% power to detect hazard
ratios between 0-76 and 1.31 at the 5% level of
significance, assuming that 45% of the aci-
clovir group would have signs or symptoms at
day five. This is equivalent to detecting an
arithmetic reduction of 10% (45% to 35%) in
the proportion of patients still having signs or
symptoms at day 5. Smaller treatment differ-
ences were considered clinically unimportant;
therefore, if the resulting 95% confidence
intervals for the hazard ratio [95% CII fell
within these clinically unimportant ranges, the
power of the study was such that equivalence
could be concluded.
STATISTICAL ANALYSIS
The data listing and statistical analyses were
performed using Statistical Analysis Systems
software version 6-07 (SAS Institute Inc,
ill
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Cary, NC, USA). The intent to treat analysis
group was defined as all patients randomised
who returned to the clinic for assessment of an
HSV recurrence. This group was used for the
analysis of the primary efficacy endpoint of
episodic length and relevant secondary end-
points, as well as for exploratory analyses and
the evaluation of safety. Patients in whom
vesicular/ulcerative lesions were prevented
were excluded from the analysis of lesion heal-
ing time. Patients for whom there was no posi-
tive HSV culture result during treatment or
follow up were excluded from the analysis of
duration of virus shedding.
The distributions of time to event endpoints
(length of episode, lesion healing time, dura-
tion of pain/discomfort, and duration of viral
shedding) were estimated using the Kaplan-
Meier product limit method. With the excep-
tion of duration of viral shedding, all other
times to event were calculated in hours, from
signs or symptom onset as recorded in patient
diaries. Cox's proportional hazards models
were used to estimate treatment differences.
Formal hypothesis testing was performed for
length of episode. The Cochran-Mantel-
Haenszel test was used to investigate treat-
ment differences in the percentages of patients
with pain/discomfort on days three and seven
and in those in whom vesicular/ulcerative
lesions were prevented. Odds ratios were also
derived for percentages of patients in whom
lesions failed to progress to vesicles/ulcers.
Since previous studies have identified sex as an
important factor influencing efficacy,'8 19 it was
included as a covariate in the Cox's propor-
tional hazard models or logistic regression
models as appropriate. Hodges-Lehmann esti-
mates [95% CI] were used to assess any treat-
ment differences or changes over time in
haematology and biochemistry variables. All
adverse experience data were tabulated and
compared across the two treatment groups.
Additional exploratory analyses were con-
ducted on episode length, lesion healing time,
and percentages of patients in whom vesicu-
lar/ulcerative lesions were prevented. Age
(years) and time from prodrome/first sign to
initiation of therapy (hours) were fitted as con-
tinuous variables; prior use of suppressive aci-
clovir therapy (used v not used), and number
of recurrences in the previous year (S 8 v
Table 1 Demographic characteristics and HSV disease history
Valaciclovir Aciclovir
(n = 378) (n = 361)
Median age (years) (range) 32 (18-77) 33 (20-74)
Sex (%) male/female 50/50 49/51
Median time from first genital HSV
episode (years) 3-66 4-15
No of recurrences in previous year (%)
1-3 3 3
4-8 60 68
9 37 29
Use of suppressive aciclovir in previous year 17% 14%
Median time on suppressive therapy (years) 0 34 0.34
HSV culture before or at screening
HSV-2 29-9% 25-5%
HSV-1 0-8% 1-7%
Not typed 11-6% 12-7%
HSV-2 infection confirmed by serology* 57-7% 60-1%
*Performed on patients without documented positive HSV culture at genital site.
. 9) were also incorporated as covariates into
the models in order to identify their impact on
the clinical endpoints.
PLASMA ACICLOVIR LEVEL MONITORING AND
PHARMACOKINETIC ANALYSIS
Plasma aciclovir concentrations for subjects in
each treatment group were plotted as a func-
tion of time after the last dose. Mean concen-
tration v time profiles for valaciclovir and
aciclovir recipients were estimated using non-
linear mixed effect modelling (NONMEM
version 4).20
Results
PATIENT CHARACTERISTICS
In all, 999 patients were randomised to treat-
ment at 48 study sites in Europe and
Australia. The intent to treat group consisted
of 739 patients who returned for clinic assess-
ment. Overall, 59% of treated patients did not
have a documented positive culture for HSV
at a genital site and required serological confir-
mation (table 1). In total, 378 patients were
treated with valaciclovir and 361 received aci-
clovir. Those patients who did not return to
the clinic were unlikely to have had a recur-
rence and therefore would not have com-
menced study drug treatment.
The demographic characteristics and HSV
disease history of treated subjects at screening
are shown in table 1 and were similar in the
valaciclovir and aciclovir groups. The sex split
was equal in both groups; ages ranged from 18
to 77 years (median 32 years). HSV disease
history was similar in the valaciclovir and aci-
clovir groups although slightly more patients
in the valaciclovir group had experienced > 9
recurrences in the previous 12 months com-
pared with the aciclovir group (37% v 29%).
The median time from the initial HSV episode
was approximately four years. Overall,
14%-17% had received suppressive aciclovir
therapy in the previous year for a median time
of four months. A positive HSV culture was
recorded for 41% of patients before enrol-
ment. The slight imbalance noted in previous
HSV recurrence frequency necessitated rou-
tine inclusion of this factor as a covariate in
the efficacy analyses. There were insufficient
numbers of patients with proved HSV-1 infec-
tion (1%-2%) for separate analysis.
ANALYSIS OF EFFICACY
Length of episode
No significant difference between valaciclovir
and aciclovir was detected in length of
episode, as evidenced by the hazard ratio
[95% CI] of 0.93 [079, 1.08]. p = 034
(table 2). The median episode duration for the
valaciclovir and aciclovir groups was 4.7 and
4.6 days respectively (fig 1).
Lesion healing
In those patients with lesions that progressed
to vesicles/ulcers, complete re-epithelialisation
occurred as rapidly with valaciclovir as aci-
clovir. The hazard ratio [95% CI] for valaci-
clovir v aciclovir was 0-96 [0-80, 1.14] (table
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Table 2 Valaciclovir versus aciclovirfor recurrent genital herpes: time to event endpoint
Valaciclovir v aciclovir
Hazard ratio Median time to
(95% CI) event (days)
Length of episode* 0 93 (0.79, 1.08) p = 034 4-7 v 4-6
Lesion healingt 0-96 (0-80, 1-14) 4-4 v 4-5
Duration of pain/discomfort4:
overall 0.91 (0-78, 1-06) -¶
males 0-89 (0-71, 1-12) 2-5 v 2-0
females 0.97 (0.77, 1-22) 3.0 v 3.0
Duration of virus shedding§:
overall 0-98 (0.75, 1-27) 2 v 2
males 0 93 (0-65, 1-33) 2 v 2
females 0.95 (0-61, 1-47) 2 v 2
*Time from treatment initiation to resolution of all signs and symptoms (n = 710).
tDefined as loss of crusts and re-epithelialisation, includes only patients who develop
vesicular/ulcerative lesions (n = 559).
tAll patients (n = 712).
§Patients with > 1 positive HSV culture (n = 295).
¶Proportional hazards assumption not satisfied for sex, therefore separate analyses of males at
females was necessary.
Figure 1 Kaplan-Meier
plot ofpercentages of
patients with signs or
symptoms of a genital
herpes recurrence following
treatment with valaciclovir
or aciclovir.
Figure 2 Kaplan-Meier
plot ofpercentages of
patients with cutaneous
lesions of a genital herpes
recurrence notyet healed
following treatment with
valaciclovir or aciclovir.
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Table 3 Valaciclovir versus aciclovirfor recurrent genital herpes: prevention of lesion
development, pain, and virus shedding proportions
Valaciclovir v
aciclovir
Relative risk
Valaciclovir Aciclovir (95% CI)
Percentage in whom vesicular/ulcerative
lesions were prevented
overall 22 21 1-08 (0-82, 1-4
males 20 18 1-26 (0-82, 1 9
females 24 24 0-96 (0-67, 1-3
Percentage with pain on day 3*
none 40 42 0.30t
mild 43 42
moderate/severe 11 11
Percentage with pain on day 7t
none 50 52 0 87t
mild 4 2
moderate/severe 1 1
Percentage with no positive HSV culture 59 54 ND
*Pain scores missing for some patients.
tCochran-Mantel-Haenszel statistic.
ND = not determined.
ts 2). Median healing times were 4-4 and 4.5
days for the valaciclovir and aciclovir groups
respectively (fig 2).
Prevention of vesicularlulcerative lesions
The percentages of patients in the valaciclovir
and aciclovir groups in whom vesicular/ulcera-
tive lesions were prevented was similar, at 22%
and 21% respectively, and did not differ with
sex (table 3). The odds ratio [95% CI] for the
chance of vesicular lesions being prevented
with valaciclovir treatment compared with aci-
d clovir was 108 [0.82, 1.42].
Pain/discomfort
nd No differences between valaciclovir and aci-
clovir were evident in the percentages of
patients experiencing no/mild pain or moder-
ate/severe pain on day 3 or day 7 (table 3).
Resolution of pain/discomfort was achieved as
. rapidly with valaciclovir as aciclovir in allpatients and in males and females when
analysed separately. Hazard ratios [95% CI]
indicated no treatment differences (table 2).
Virus shedding
In patients with at least one swab for HSV cul-
ture, results were all negative in similar pro-
portions in each treatment group, at 59% for
valaciclovir and 54% for aciclovir (table 3).
For those in whom at least one culture was
16 positive during treatment or follow up, termi-
nation of virus shedding was as rapid in each
group, as evidenced by the hazard ratio [95%
CI] for valaciclovir v aciclovir of 0.97 [0.75,
1.26], with no differences being apparent
between the sexes (table 2).
vir|
Exploratory analyses
Results of the exploratory analyses suggest that
episode resolution was 20% faster in those
patients who had previously received suppres-
sive aciclovir therapy in the year before enrol-
ment compared with those who had not
(hazard ratio [95% CI] 0.80 [0-63, 1l01] p =
0.06). Earlier treatment initiation accelerated
episode resolution (hazard ratio for the differ-
16 ence [95% CI] 0 99 [0.98, 100] p = 001)
and lesion healing (hazard ratio for the differ-
ence [95% CI] 0.99 [0.98, 1-00] p = 0.03).
Hence, in patients starting treatment six hours
after first signs/symptoms, episode resolution
and lesion healing were 15% and 13% faster,
respectively, than in those starting treatment
24 hours after first signs/symptoms.
ANALYSIS OF SAFETY
Adverse experiences reported during treat-
L2)
'3) Table 4 Adverse experiences reported by > 2% of
,7) patients
Valaciclovir Aciclovir
n =378 n =361
Adverse experience (%) (%)
Headache 14 9
Nausea 8 8
Diarrhoea 2 5
Abdominal pain 3 3
Asthenia 3 3
Dizziness 2 2
Insomnia 2 1
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ment and follow up, irrespective of associa-
tion, which occurred in > 2% of subjects, are
listed in table 4. The most frequent were
headache and nausea; no major differences
between treatments were evident. Headache
was considered possibly attributable to valaci-
clovir or aciclovir in 10% and 7% of patients,
with nausea thought possibly attributable in
8% and 7%, respectively. Three adverse expe-
riences in three patients were considered seri-
ous, but only one, a patient receiving aciclovir
who suffered abdominal pain, was thought
possibly attributable to the drug. Treatment
was discontinued prematurely in five patients
(valaciclovir three, aciclovir two) as a result of
adverse experiences.
There were no clinically important changes
from screening in any haematology or clinical
chemistry variable with valaciclovir or aciclovir
treatment or differences between groups dur-
ing treatment or between values from samples
taken on day one and day five. Mean serum
creatinine values (SD) on day one were 87.9
(14-7) and 87.2 (13-2) FM for the valaciclovir
and aciclovir groups, respectively. On day five,
respective mean values were 87-9 (14-1) and
87.5 (13-8) FtM, indicating no meaningful dif-
ferences between the groups or with treat-
ment.
PLASMA ACICLOVIR LEVEL MONITORING
Estimated mean peak aciclovir concentrations
for patients randomised to valaciclovir and aci-
clovir were 12.3 FtM (2.8 [ig/ml) and 2-9 FtM
(0.65 [tg/ml) respectively. Corresponding esti-
mates of the areas under the aciclovir plasma
concentration v time curves over 24 hours
were 99.5 tAM/h (22A4 h/4g/ml) and 49.3 [tM/h
(11 1 h/tg/ml). Thus, the 500 mg valaciclovir
regimen increased the systemic exposure to
aciclovir by twofold over the standard oral
aciclovir regimen. Since a 500 mg dose of
valaciclovir contains approximately 347 mg
aciclovir, the bioavailability of aciclovir from
valaciclovir 500 mg twice daily was 2.9 times
greater than that from aciclovir 200 mg five
times daily in this study.
Discussion
This study has found that valaciclovir at a dose
of 500 mg twice daily for five days and aci-
clovir at the standard dose of 200 mg five
times daily also for five days are equally effec-
tive in patient initiated treatment of recurrent
genital herpes. Moreover, this clinical equiva-
lence is achieved without apparent compro-
mise to the excellent safety profile established
for aciclovir. This was one of two large trials
conducted to examine a 500 mg twice daily
regimen of valaciclovir, after an earlier placebo
controlled study of similar design demon-
strated that 1000 mg was as effective as the
standard aciclovir regimen in shortening all
signs and symptoms of a recurrence.'6 The
companion study has shown 500 mg and 1000
mg unit doses of valaciclovir taken twice daily
to be equivalent for the same efficacy end-
points and both to be superior to placebo.'5
From this and the results of the present study,
it may be concluded that valaciclovir 500 mg
twice daily achieves the same clinical efficacy
in treating genital herpes recurrences as the
standard oral aciclovir regimen.
The five times a day dosing regimen for aci-
clovir for recurrent genital herpes has been
supported by several clinical studies8 9 16 21 22
and is currently recommended by the US
Centers for Disease Control and Prevention.6
An effective twice daily treatment regimen for
recurrent genital herpes may confer benefits in
addition to the greater convenience and
improved compliance usually attributed to
simplified dosing schedules. There is a degree
of general community awareness of the indica-
tions for aciclovir (Zovirax). Consequently,
many patients with anxiety about the potential
social consequences of their diagnosis, includ-
ing fear of detection, will appreciate a regimen
that allows all treatment to be taken (and
stored) in the privacy of the home.
Simulated plasma aciclovir concentration v
time profiles indicated that the 500 mg twice
daily valaciclovir regimen would increase sys-
temic aciclovir exposure by 1.5 to 2-fold com-
pared with that following oral aciclovir."3
Plasma aciclovir level monitoring in this study
in young adults with genital herpes, a popula-
tion of similar age to that in the formal phase 1
study, has confirmed that at steady state,
500 mg twice daily valaciclovir does result in
the predicted doubling of aciclovir exposure.
The results of this study have demonstrated
both the clinical and statistical equivalence in
efficacy of valaciclovir and the standard oral
aciclovir regimen on the primary endpoint. We
believe that the study was adequately pro-
tected against type 2 error; a 10% difference in
the number of patients with signs or symptoms
at day 5 could have been detected with 80%
power. Although not statistically powered for
hypothesis testing on all the other efficacy end-
points, analyses consistently indicated in each
case no evidence for any meaningful differ-
ences between treatment groups. Of particular
clinical importance are the results showing
that vesicular lesions were prevented in similar
percentages of patients and that in 59% and
54% of valaciclovir and aciclovir recipients,
respectively, no HSV culture was positive once
treatment had begun.
The primary efficacy endpoint, length of
episode, encompasses all clinical signs and
symptoms, specifically the more traditional
measure of cutaneous lesion healing plus reso-
lution of pain, itching, or other discomfort.
The intent to treat population, on which the
primary time to event analysis of length of
episode was based, thus comprises two sub-
populations defined according to clinical out-
come-those in whom clinically evident skin
lesions progress through all stages of healing
and those whose initial symptoms indicated a
pending recurrence but which subsequently
fails to develop beyond the papule stage
(aborted episode). Lesions that fail to progress
have been recognised in several earlier clinical
trials of aciclovir and represent the most desir-
able clinical outcome.8-'0
Patient initiated treatment is designed to
14
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minimise the time from onset of symptoms to
commencement of therapy. Studies comparing
patient and physician initiated treatment for
acute episodes of genital herpes have sup-
ported the patient initiated approach for oral
aciclovir.5 1 Exploratory analyses in the pre-
sent study lend further support for this strat-
egy, having shown that both episode duration
and lesion healing are briefer with earlier treat-
ment. However, the time from symptom onset
to starting treatment did not influence the
number of patients in whom vesicular lesions
were prevented. One possible explanation may
be the protocol requirement for patients to ini-
tiate treatment within 24 hours of any symp-
tom of a recurrence, including skin lesions
alone; this would not necessarily ensure pro-
dromal treatment and would not optimise the
chances of even earlier termination of HSV
replication and prevention of skin damage.
Future studies to address this desirable clinical
outcome should include patients with pro-
drome only.
We found that in patients who had used
suppressive aciclovir therapy in the 12 months
before enrolment, resolution of the episode
was on average 20% faster than in patients
who had not. An explanation for this is not
readily apparent as suppressive therapy is con-
sidered to affect the course of HSV disease
only during the period of treatment and the
subsequent recurrence rate is not affected even
by prolonged therapy.'92324 The availability of
aciclovir for long term suppression of genital
herpes is such that studies of its long term ben-
efits have only been possible for a maximum
period of 10 years.2226 For an infection such as
genital HSV that persists throughout life, and
as evidenced by the current study in which the
oldest patients were 77 years of age, 10 years is
probably not an adequate period on which to
draw conclusions regarding the natural his-
tory.
The safety profile of aciclovir has been care-
fully established over more than 12 years of
clinical use.5 11 In the current study, there were
no clinically significant differences in the
nature, frequency, or severity of adverse events
between treatment groups, and no haematol-
ogy or clinical chemistry variable was signifi-
cantly affected during treatment. Previous
placebo controlled trials of aciclovir or valaci-
clovir in the acute treatment of recurrent geni-
tal herpes in immunocompetent adults have
shown that adverse events occurred in similar
percentages of patients receiving the active
treatments and placebo, suggesting that such
events are typical of the disease rather than a
result of therapy with aciclovir or valaci-
clovir.789156 Although the daily area under the
plasma aciclovir concentration v time curve
after valaciclovir was twice that following aci-
clovir, and peak plasma concentrations were
approximately four times greater after valaci-
clovir, no meaningful changes in serum creati-
nine values were detected during treatment
with valaciclovir or aciclovir.
The present study has demonstrated that
twice daily valaciclovir is as effective as the
standard five time daily aciclovir regimen in
rapidly resolving the signs and symptoms of an
episode of recurrent genital herpes.
Valaciclovir confers all the clinical benefits of
aciclovir but with the convenience and security
of a twice daily dosing regimen and without
apparent compromise to aciclovir's excellent
safety profile.
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Gram's stain
Hans Christian Joachim Gram was born in
Copenhagen in 1853, the son of a professor of law. He
qualified in medicine in 1878, and after holding junior
posts he joined a course in microbiology. His tutor
formed a high opinion of him, and asked Carl
Friedlander if he could study in his laboratory in
Berlin. He arrived there in 1883, and almost at once
embarked on an investigation into the problem of iden-
tifying bacteria in stained tissue sections. The tech-
niques in use at this time made this difficult because
cell nuclei, fibrin, and bacteria stained with equal
intensity. Gram found that if he applied a solution of
iodine and potassium iodide to sections already stained
with gentian violet, then immersed them in absolute
alcohol, he could decolorise the tissue cells without
changing the deep blue colour of many bacteria.
Subsequently, he found it useful to counterstain the tis-
sue with Bismarck or aniline brown.
Three weeks after his arrival in Berlin, Gram wrote
to his tutor in Copenhagen: "I have had the good luck to
find what seems to be a very good method of staining
cocci while the tissue and cell nuclei remain unstained.
Dr F is delighted with the method." Friedlander soon
mentioned Gram's method in a paper on the micro-
cocci of pneumonia, then Gram himself published a
detailed account of it. By this time, he had found that it
could be applied to smears as well as tissues, so that it
was possible to distinguish bacteria which retained their
blue colour after the iodine/alcohol treatment ("Gram
positive") from those which were decolorised ("Gram
negative"). He ended his paper with these words:
"Hopefully, the method will prove useful in the hands
of other investigators." Having said this, he did no fur-
ther work on the technique, leaving its refinement to
others. Having been in Berlin for only five months, he
returned to Copenhagen, where in due course he
became professor of pharmacology and senior physi-
cian at Frederik Hospital. He died in 1938 at the age
of 85 years.
Neisser first identified the gonococcus in 1879 by
staining smears of pus from the male urethra with
methyl violet, and it was soon realised that it stained
equally well with other basic aniline dyes such as gen-
tian violet and methylene blue. Gram did not try his
technique on the gonococcus himself, but in 1886
Roux wrote: "One can always recognise the true
nature [of gonococci] if, after establishing their pres-
ence with gentian violet alone, the liquid of Gram and
alcohol are successively added. If the cocci completely
disappear, they are indeed those of Neisser."
Counterstaining with Bismarck brown revealed the
organisms more clearly, but later workers found that a
better contrast was obtained with carbol fuchsin or
methyl red.
Gram staining for the diagnosis of gonorrhoea was
widely used by the end of the 19th century although
some venereologists still preferred a single stain, par-
ticularly methylene blue. A few physicians-Harrison
was one-advocated staining by methylene blue to
confirm the result of a Gram stain, but in modem
times strict protocols have made such precautions
unnecessary. Gram's is the commonest staining proce-
dure in venereology, and indeed in the whole of clinical
microbiology. In later life he was amused that he was
best known for a single discovery that he had made,
almost by chance, as a young man. He said he had
been lucky, but luck often favours those who deserve
it. J D ORIEL
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